What Fore Genomics does

Fore Genomics, Inc., a private US company headquartered in San Diego and founded in 2020 by CEO Matt Pelo, sells direct-to-consumer pediatric genetic screening. Its single core product, the At-Home Pediatric Genetic Health Screen, uses whole genome sequencing on a cheek-swab sample to screen for over 1,000 pediatric-onset conditions and 100+ medication sensitivities, with processing in CLIA-certified and CAP-accredited labs and storage on the DNAnexus platform (ISO 27001, HIPAA, GDPR, FedRAMP Moderate, CSA STAR Level 2). Results are delivered through a secure digital portal and accompanied by board-certified genetic counselor consultations, with annual re-analysis of the same sample as the scientific literature evolves.

The product is priced at $495 as a one-time purchase covering the kit, sequencing, counseling, and encrypted storage. Revenue mechanics blend a one-time transactional sale with a recurring annual re-analysis subscription, plus gift card SKUs ($100, $250, $495) that enable gifting. Go-to-market is self-serve e-commerce on a Shopify-style storefront with content-led demand generation across blog, case studies, organic social, and email capture; HSA/FSA eligibility and BBB accreditation support consumer trust. Strategic technology and go-to-market partners include DNAnexus (infrastructure), Inocras, DNA Ally, Grey Genetics (partner logos), and Celebration Stem Cell Centre (cord-blood-banking cross-sell).

The company is early-stage and bootstrapped, with no disclosed external funding and a 1-10 employee footprint including a CTO, CCO (PharmD), VP Product, VP Marketing, and Head of Growth. Customer concentration is by design diffuse, given a pure long-tail DTC consumer model, and named customers are individual families. Revenue, customer count, and growth metrics are not disclosed in the available data.

Name

Fore Genomics

Legal name

Fore Genomics, Inc.

Website

https://foregenomics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Fore Genomics is a private San Diego company selling a $495 at-home whole-genome-sequencing pediatric genetic health screen to US parents, covering 1,000+ conditions and medication sensitivities via a DTC e-commerce model.

Ownership category

akta.pro rank

Product category

Pediatric Genetic Screening

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Newborn Screening & Genetic Public Health Laboratories (HLAJAIAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Pediatric genetic screening
• Whole genome sequencing
• At-home DNA testing
• Pharmacogenomic screening
• Genetic health diagnostics

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. At-Home Pediatric Genetic Health Screen: One-time purchase of genetic screening kit at $495, includes whole genome sequencing, 1,000+ condition screening, 100+ medication sensitivity indicators, access to board-certified genetic counselors, and encrypted data storage
2. Annual Updates: Annual re-analysis of existing genome sample as new scientific discoveries emerge, providing updated reports
3. Gift Cards: Prepaid gift cards available in $100, $250, and $495 denominations for gifting the screening service

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Fore Genomics sells a direct-to-consumer At-Home Pediatric Genetic Health Screen ($495) that uses whole genome sequencing on a self-collected cheek swab to screen for over 1,000 pediatric-onset genetic conditions and 100+ medication sensitivities, with results delivered through a secure digital portal and board-certified genetic counselor consultation. The service includes annual re-analysis of the stored genome as new scientific discoveries emerge, and is supported by CLIA/CAP-accredited lab processing and HIPAA-compliant encrypted data storage.

Product overview

Fore Genomics offers a single unified product—the At-Home Pediatric Genetic Health Screen—which uses whole genome sequencing (WGS) to screen for over 1,000 pediatric-onset genetic conditions and 100+ medication sensitivities from an at-home cheek swab. The service is priced at $495 and includes sample collection kit, CLIA/CAP accredited lab processing, secure digital results portal, genetic counselor consultation, and annual re-analysis updates. The company also offers Gift Cards in $100, $250, and $495 denominations for gifting the screening service.

Differentiator

Problem solved

Functional benefit

Products and services

• At-Home Pediatric Genetic Health Screen A direct-to-consumer, at-home genetic screening service that uses whole genome sequencing on a self-collected cheek swab to screen for over 1,000 pediatric-onset genetic conditions and 100+ medication sensitivity indicators. Includes CLIA/CAP-accredited lab processing, secure digital results portal, board-certified genetic counselor consultation, physician-ready clinical reports, and annual re-analysis of the stored genome as new science emerges; intended for parents seeking proactive preventive healthcare for newborns and young children.
• Fore Genomics Gift Card A prepaid digital gift card redeemable on the Fore Genomics website for the At-Home Pediatric Genetic Health Screen. Available in $100, $250, and $495 denominations and used by customers purchasing the screening as a gift for another family.

Quantifiable outcome

• Nearly 10% of pediatric hospital admissions are due to adverse drug reactions - Fore's pharmacogenomics testing can help reduce this risk
• +2 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• DNAnexuscoreTechnology or IntegrationDNAnexus is Fore Genomics' primary data storage and management partner. The platform is trusted by leading hospitals and research institutions worldwide. DNAnexus maintains rigorous compliance with ISO 27001, HIPAA, GDPR, and NIST 800 standards including FedRAMP Moderate Authorization. All genetic data is encrypted and stored in high-security facilities under strict access controls.
• Celebration Stem Cell CentreminorStrategic or Co-development PartnerCelebration Stem Cell Centre partnered with Fore Genomics to offer pediatric genetic screening services alongside cord blood banking. This partnership provides families with a combined approach of genetic insight and stem cell preservation for future therapeutic options.

Recent moves6 records

Expansion highlights6 records

Direct peers

• 23andMe: Once the dominant DTC genetic testing brand; Fore competes in the same direct-to-consumer DNA test category with at-home saliva/swab collection and online results, though Fore is pediatric-focused and uses whole genome sequencing rather than genotyping arrays.
• Nebula Genomics: DTC whole genome sequencing company offering at-home WGS with deep-coverage analysis and optional ongoing insights — closest direct competitor to Fore on the WGS-plus-ongoing-reanalysis value proposition.

Emerging players

• Color Health: DTC-adjacent clinical genetic testing company with hereditary cancer, PGx, and population genomics offerings; competes with Fore on the proactive health testing concept and on pharmacogenomics, with stronger enterprise and employer channels.
• Variantyx: Clinical genomics lab specializing in whole genome sequencing for rare disease diagnostics; comparable to Fore on the WGS technology stack and pediatric/rare-disease focus, but operating in the provider-ordered channel.
• Helix: Population genomics and clinical sequencing company operating a CLIA/CAP lab with a marketplace of DNA-powered apps; overlaps with Fore in the whole-exome/genome clinical infrastructure and in serving consumers through digital results.

Broad incumbents

• Natera: Established clinical genetic testing lab with pediatric and reproductive health offerings including pharmacogenomics; a broader incumbent in the same clinical genetic testing space where Fore operates its pediatric-focused niche.
• Myriad Genetics: Long-established clinical genetic testing company with a broad menu including hereditary cancer, pharmacogenomics, and rare disease panels; overlaps with Fore in the genetic and pharmacogenomic testing layer at a much larger, provider-channel scale.
• PerkinElmer Genomics: Clinical genomics and newborn screening services business of a large life-sciences tools company; direct overlap with Fore on the pediatric and newborn screening category, accessed primarily through clinicians and state public health programs.
• GeneDx (formerly Sema4): Clinical genomics laboratory offering pediatric and rare disease whole genome and exome sequencing ordered through healthcare providers; competes with Fore on the pediatric clinical genomics content but accesses customers via clinicians rather than DTC.

Regional players

• Mapmygenome: DTC and clinical genetic testing company in India offering whole genome and panels for proactive health; comparable business model to Fore (DTC, at-home, health-focused) but primarily serving a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ForeGenomics
• LinkedInlinkedin.com/company/foregenomics
• Instagraminstagram.com/foregenomics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fore Genomics